Loomis Sayles & Co. L P Has $10.42 Million Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Loomis Sayles & Co. L P trimmed its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 174,617 shares of the specialty pharmaceutical company’s stock after selling 6,831 shares during the period. Loomis Sayles & Co. L P owned approximately 0.83% of ANI Pharmaceuticals worth $10,418,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of ANI Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock worth $90,314,000 after buying an additional 17,460 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of ANI Pharmaceuticals by 3.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock valued at $40,132,000 after purchasing an additional 21,053 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after purchasing an additional 565,910 shares during the last quarter. Global Alpha Capital Management Ltd. increased its position in ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in ANI Pharmaceuticals by 3.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock valued at $14,936,000 after purchasing an additional 8,869 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of research reports. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price for the company. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Raymond James upped their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $59.39 on Thursday. The business has a 50-day moving average of $58.32 and a 200-day moving average of $60.76. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -105.20 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the previous year, the company earned $1.05 EPS. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 33,981 shares of company stock valued at $1,970,066. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.